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Adult male rat hepatocytes, which normally respond poorly to /3-adrenergic agents, acquire such 
responsiveness during primary monolayer culture. We here show that the rise in catecholamine-sensitive 
adenylate cyclase activity in hepatocytes in vitro is closely paralleled by an increase in the ability to bind 
the ,&adrenoceptor ligand [1251]cyanopindolol. The emergence of fl-adrenergic responsiveness did not 
require cell attachment or serum. Addition of dexamethasone, insulin, thyroxine or dihydrotestosterone 
to the cultures, singly or in combination, did not prevent the augmented&adrenergic responsiveness. The 
increase in catecholamine-sensitive adenylate cyclase activity and [r2’I]cyanopindolol binding could be 
blocked by cycloheximide or actinomycin D. Exposure of the cultures to isoproterenol at 3-hourly intervals 
led to a dose-dependent suppression of the rise in isoproterenol-responsive adenylate cyclase and prevented 
the increase in ,&adrenoceptor binding. 
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1. INTRODUCTION 
In liver or freshly isolated hepatocytes from nor- 
mal adult male rats, the adrenergic regulation of 
carbohydrate metabolism is mainly an a-type 
rather than a P-type effect [l-5], and the cyclic 
AMP system is relatively insensitive to 
catecholamines [3,5-81. However, a number of 
physiological and pathological conditions have 
been recognized, including ontogenetic immaturity 
[7-g], glucocorticoid deficiency [lo- 121, ex- 
perimental diabetes [ 131, hypothyreosis [ 141, 
Abbreviations: MIX, methylisobutylxanthine; ICYP, 
iodocyanopindolol; CHX, cycloheximide; Act. D, ac- 
tinomycin D 
estrogen influence [ 10,151, regeneration [ 161, 
cholestasis [5,17] and preneoplasia [6,8,18], in 
which the P-adrenergic mechanism via the 
adenylate cyclase is operational in the liver. 
Recently it was demonstrated that when 
hepatocytes are kept in primary monolayer 
culture, a shift occurs from a predominantly LY- 
adrenergic to a &adrenergic control of glycogen 
phosphorylase [ 191. Concurrently, the cells acquire 
a strongly increased cyclic AMP [8,19-211 and 
adenylate cyclase Wll response to 
catecholamines. We have investigated some of the 
mechanisms underlying this increase in ,B- 
adrenergic responsiveness. Our studies showed 
that the rise in catecholamine-sensitive adenylate 
cyclase activity in cultured hepatocytes was 
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associated with an increase in the number of fl- 
adrenergic receptors, did not require cell attach- 
ment, and could be blocked by inhibitors of pro- 
tein and RNA synthesis or by exposure of the 
cultures to the P-agonist isoproterenol. 
Preliminary reports have appeared [22,23]. 
After this work was completed an independent 
study was published which similarly provides 
evidence that the acquisition of increased p- 
adrenergic response during primary culture of 
hepatocytes is due to new synthesis of ,&adrenergic 
receptors [24]. 
2. MATERIALS AND METHODS 
2.1. Materials 
( *)-[‘251]Cyanopindolol (2200 Ci/mmol) was 
from New England Nuclear (Boston). 
( - )Propranolol hydrochloride was a gift from Im- 
perial Chemical Industries (London). The sources 
of other chemicals and radioisotopes have been 
described [25]. 
2.2. Hepatocyte isolation and culture 
Male Wistar rats, 180-220 g, were fed ad 
libitum. Hepatocytes were isolated as in [26]. For 
culturing [27], the hepatocytes were washed twice 
in Dulbecco’s Modified Eagle’s Medium and seed- 
ed in the same medium (5-6 x lo5 cells/ml) sup- 
plemented with 15% horse serum, 2.5% fetal calf 
serum, penicillin (100 units/ml), streptomycin 
(0.1 mg/ml) and other additions as indicated, us- 
ing Costar culture flasks of varying size with 
0.12 ml medium/cm2. 
2.3. Assay of cyclic AMP and adenylate cyclase 
activity 
The cyclic AMP response in intact suspended or 
monolayer cells was measured [25] after washing, 
addition of Krebs-Ringer Hepes buffer, equilibra- 
tion for 45 min at 37”C, and incubation for 60 s 
with the agonist to be tested in the presence of 
0.5 mM methylisobutylxanthine. 
For assay of adenylate cyclase activity, the cells 
were washed and lysed by hypotonic treatment for 
2 min followed by freezing/thawing as in [25]. In- 
cubations were carried out with -100 pg lysate 
protein in 100~1 total volume at 0.2 mM ATP 
(containing -IO6 cpm [a32P]ATP). Other details 
have been described [25]. The labelled cyclic AMP 
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formed was purified on Dowex-SO/alumina double 
columns [28]. 
2.4. ,B-Adrenergic binding 
,&Adrenoceptor binding was assessed by in- 
cubating washed particles with ( +)-[‘251]cyanopin- 
dolol [29]. The cells were lysed as described above, 
the lysates were suspended in 50 mM Tris (pH 7.5), 
30 mM KCl, 4 mM MgCL, and particles were 
prepared by centrifuging at 40000 x g for 20 min, 
washing and respinning. Samples (35-100 ,ug par- 
ticle protein) were incubated at 37°C for 90 min in 
50 mM Tris (pH 7.4) and 10 mM MgCL in 200~1 
total volume with varying concentrations of 
[1251]cyanopindolol and unlabelled ligands. Bound 
ligand was separated from the free fraction by 
filtration through Whatman GF/C filters. Specific 
binding was defined as the difference in the 
amount of bound radioactive ligand obtained in 
the absence and in the presence of 0.3,uM 
( - )propranolol. 
3. RESULTS 
3.1. Increased catecholamine-responsive adenylate 
cyclase activity in cultured hepatocytes; Pz- 
characteristics 
Hepatocytes in primary culture acquire an in- 
creased catecholamine-sensitive adenylate cyclase 
activity [8,21]. Fig. 1 shows dose-response curves 
for isoproterenol on the adenylate cyclase in 
hepatocytes assayed immediately after isolation 
and after 48 h in monolayer culture. The order of 
potency of adrenergic agents (isoproterenol > 
epinephrine % norepinephrine, fig. 1, inset) in- 
dicated that the strong response evolving in vitro 
was of the flz-type. 
3.2. Cell attachment or serum not required 
In order to decide if the increased response of 
the hepatocytes in monolayer culture to P- 
adrenergic agents was a result of the attachment of 
the cells to the substratum (which conceivably 
might affect the adenylate cyclase through changes 
in the cytoskeletal organization [30]) we carried 
out parallel experiments (table 1) on cells that were 
inoculated into culture flasks and either allowed to 
form monolayers or prevented from plating by 
continuous low-speed rotatory shaking. After 7 h 
there was a substantial and equal increase in the 





Fig. 1. Catecholamine-responsive adenylate cyclase in 
cultured hepatocytes. Dose-response curve for 
isoproterenol (with 100 FM GTP) on the enzyme in rat 
hepatocytes immediately after isolation (0 h) and after 
48 h in monolayer culture. Mean of duplicate 
measurements from one typical experiment. Inset: 
Relative effect of isoproterenol (--o-), epinephrine 
(-t-) and norepinephrine (-A--) on the adenylate 
cyclase activity in hepatocytes cultured for 24 h. (In the 
experiment shown in the inset the cells were seeded with 
0.4 ,uM insulin plus 0.25 FM dexamethasone.) 
isoproterenol responsiveness in both the suspended 
and the plated cells, in terms of adenylate cyclase 
activity (not shown) as well as cyclic AMP 
response (table 1). It thus appears that the increas- 
ed ,&adrenergic responsiveness acquired by the 
liver cells in vitro is not attachment-dependent. 
The increased isoproterenol response, measured 
as ability to accumulate cyclic AMP (table 2) or 
adenylate cyclase activity (not shown) was obtain- 
ed also in monolayers that had been cultured 
without serum. 
3.3. Failure of insulin, dexamethasone, thyroxine 
and testosterone to suppress the rise in 
catecholamine response of the adenylate 
cyclase 
Enhanced ,&adrenergic response has been found 
after adrenalectomy [lo- 121, in hypothyreosis [141 
and in diabetes [ 131, and androgen administration 
in vivo lowered the hepatic epinephrine-sensitive 
adenylate cyclase activity [lo]. It was thus con- 
ceivable that deprival of hormonal factors in the in 
vitro triggered the emergence of the fl-adrenergic 
responsiveness. Table 3 shows that insulin, dex- 
amethasone, thyroxine and dihydrotestosterone, 
singly or in combination, did not suppress the 
development of a highly isoproterenol-sensitive 
adenylate cyclase activity in the cultured 
hepatocytes. (Insulin and dexamethasone improve 
the plating efficiency and viability of the 
hepatocytes [21]. Therefore, these hormones were 
routinely used in the subsequent experiments.) 
3.4. Parallel increment in ,8-adrenoceptor binding 
and catecholamine-sensitive adenylate cyclase 
activity 
Table 1 
Cyclic AMP response to isoproterenol and glucagon in hepatocyte suspensions and monolayers 
Conditions No stimulator Isoproterenol Glucagon 
(50 PM) (1.4 PM) 
pmol Cyclic AMP/mg proteina 
Suspensions (freshly isolated) 3.0 f 1.1 4.1 f 1.2 92.9 +_ 4.1 
Monolayers (7 h in vitro) 2.5 i 0.6 26.4 f 1.7 39.0 * 0.7 
Suspensionsb (7 h in vitro) 1.4 f 0.6 32.0 f 0.7 45.5 f 0.7 
a Incubation for 60 s in the presence of 0.5 mM MIX. Mean f SEM of results from 3 culture flasks 
b Cells inoculated into culture flasks were prevented from plating by continuous rotatory shaking 
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Table 2 
Cyclic AMP response in hepatocyte monolayers in the presence and absence of serum 
Conditions No stimulator Isoproterenol Glucagon 
(50 FM) (1.4 PM) 
pmol Cyclic AMP/mg proteina 
Freshly isolated cells 4.0 + 1.2 8.0 + 2.1 79.2 + 9.1 
Monolayers with serum (24 h)b 8.0 + 1.9 93.7 t- 11.5 79.1 +- 8.2 
Monolayers without serum (24 h) 7.5 + 1.9 63.6 k 7.0 70.6 k 14.2 
a Incubation for 60 s in the presence of 0.5 mM MIX. Mean f SEM of results from 3 culture flasks 
b 15% horse plus 2.5% fetal calf serum 
Table 3 
Effect of hormone pretreatment of cultured hepatocytes on isoproterenol-responsive 
adenylate cyclase 
Conditions Basal activity Isoproterenol 
(50 PM) 
pmol Cyclic AMP .mg 
protein-‘. mini 
Freshly isolated hepatocytes 1.7 + 0.5 2.4 + 0.9 
Hepatocyte monolayersb 
No addition 1.4 f 0.4 7.0 * 0.8 
Dexamethasone (0.25 PM) 1.9 * 0.4 9.1 + 0.6 
Insulin (0.4 PM) 1.9 + 0.3 8.7 + 0.3 
Dexamethasone + insulin 1.9 + 0.5 8.8 5 0.8 
Thyroxine (1 PM) 1.8 + 0.4 7.1 * 0.5 
Dihydrotestosterone (10 rg/ml) 2.6 + 0.1 7.1 + 0.6 
Dexamethasone + insulin + thyroxine + 
dihydrotestosterone 3.3 + 0.4 8.7 f 1.3 
a Adenylate cyclase was assayed with lOO/rM GTP. Mean + SEM of determinations 
on 4 separate cell preparations for the freshly isolated cells, or from 3-4 separate 
monolayer cultures for each type of in vitro treatment 
b The agents indicated were added at the time of plating. The cells were harvested for 
assay at 20 h 
Incubation of washed hepatocyte 40000 x g par- 
ticles with [1251]cyanopindolol revealed an increas- 
ed ability of the cultured cells to bind this fl- 
adrenoceptor ligand (fig.2). After 24 h of culture 
the apparent number of ,&adrenergic receptors had 
increased from 1.9 + 0.9 fmol/mg crude particle 
protein (n = 4) to 25.2 f 3.1 fmol/mg (n = 4). The 
experiments also demonstrated a close correlation, 
temporally and quantitatively, between the pro- 
gressive increase in [‘*‘I]cyanopindolol binding 
and the rise in isoproterenol-sensitive adenylate 
cyclase activity, indicating that the emerging P- 
adrenergic responsiveness of these cells in culture is 
a result of the appearance of ,L?-adrenoceptors. 
3.5. Inhibitory effects of cycloheximide and 
actinomycin D 
The increase in both &adrenergic adenylate 
cyclase activation and number of @receptors ap- 
parently was dependent on protein synthesis, since 
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Fig.2. Time course of the increase in isoproterenol- 
sensitive adenylate cyclase (-t) and ,&adrenoceptor 
binding (-o-) in primary hepatocyte cultures. The cells 
were cultured in the presence of dexamethasone 
(0.25 PM) plus insulin (0.4 pM). The adenylate cyclase 
values represent the activation above basal activity 
(range 1.1-2.0 pmol.mg-‘emin-‘) produced by 
isoproterenol (50aM). GTP was present (100,~M). /3- 
Adrenoceptor binding was assessed in incubations of 
hepatocyte particles with 45 pM [1Z51]cyanopindolol. 
The results are the means f SEM (brackets) of 
measurements on 3-6 cultures at 0, 9 and 24 h after 
plating, and the means of duplicate flasks at the other 
time points. Inset: Scatchard plot of the binding data for 
[1Z51]cyanopindolol from one of the experiments, 
comparing 0 h and 24 h of culturing. 
it was blocked almost completely by the addition 
of cycloheximide to the cultures at the time of 
seeding (fig.3). The increase was also sensitive to 
actinomycin D (fig.4), indicating a mechanism re- 
quiring gene transcription. 
Neither cycloheximide nor actinomycin D treat- 
ment reduced the glucagon responsiveness of the 
hepatocytes (fig.3,4). Thus, the inhibition by these 
agents of the increase in ,&adrenoceptor binding 
and development of highly catecholamine-sensitive 
adenylate cyclase activity was selective, and not 
merely a result of a general deterioration of plasma 
membrane function or ability to form cyclic AMP. 
In view of the reported cu-adrenergic, and slight- 
ly,&adrenergic, effect of cycloheximide [31] it was 




























Fig.3. Effect of cycloheximide on isoproterenol-sensitive 
adenylate cyclase activity and fl-adrenoceptor binding in 
cultured hepatocytes. Cycloheximide (CHX, 5 pg/ml) 
was added at 0 h. The cells were cultured for 24 h in the 
presence of dexamethasone (0.25 /cM) and insulin 
(0.4,~M). (A) Adenylate cyclase activity. Inset in A: 
Dose-response curves for isoproterenol. (B) Number of 
,&adrenoceptors, based on binding experiments with 
[1251]cyanopindolol at various concentrations. Inset in 
B: Scatchard plot. The data represent he means f SEM 
(brackets) of results from 4 experiments; the insets show 
one experiment. 
periments influence the hepatocyte adenylate 
cyclase activity when added directly to the assay 
tubes (not shown). It is thus unlikely that the 
blockade of the increase in catecholamine response 
and P-receptor number in cells pretreated with 
cycloheximide was due to a direct interaction with 
the receptor, rather than inhibition of protein syn- 
thesis. This conclusion is further corroborated by 
the fact that actinomycin D was also inhibitory. 
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Fig.4. Effect of actinomycin D on isoproterenol- 
sensitive adenylate cyclase activity and &adrenoceptor 
binding in cultured hepatocytes. Actinomycin D (Act.D, 
0.2 pg/ml) was added at 0 h. The cells were cultured for 
9 h in the presence of dexamethasone (0.25 PM) and 
insulin (0.4pM). (A) Adenylate cyclase activity. (B) 
Number of ,&adrenoceptors (see fig.3B). Inset in B: 
Scatchard plot. The data represent he means f SEM 
(brackets) of results from 4 experiments; the insets show 
one experiment. 
3.6. Suppression by isoproterenol 
Repeated additions of isoproterenol to the 
cultures (at 3-hourly intervals) prevented the rise in 
fl-adrenergic binding and response (fig.5). The 
suppressing effect of this agonist on the subse- 
quent activity of isoproterenol-sensitive adenylate 
cyclase was dose-dependent in the range of 
< 10-8-10-6 M. Glucagon-sensitive cyclase activ- 
ity was not affected (not shown). 
isoproterenol ( MI 
5 
C8 
- isoproterenol + isoproterenol 
( IO-5M 1 
Fig.5. Effect of isoproterenol-exposure on 
isoproterenol-sensitive adenylate cyclase activity (A) and 
,&adrenoceptor binding (B) in primary hepatocyte 
monolayer cultures. Isoproterenol (concentrations as 
indicated) was added to the cultures at 0, 3 and 6 h after 
the seeding. Dexamethasone (0.25 FM) and insulin 
(0.4 PM) was present. At 9 h the cells were washed 5 
times with 0.9% NaCl and harvested. Adenylate cyclase 
was assayed in the presence of lOOaM GTP, with 
(--o--) or without (+) 50pM isoproterenol. The fl- 
adrenoceptor binding was determined with 45 pM 
[‘251]cyanopindolol. The data represent the means +- 
SEM (brackets) of measurements on 3 cultures. 3 
additional experiments yielded similar results. 
4. DISCUSSION 
The present results indicate that the augmented 
&adrenergic responsiveness acquired by adult 
male rat hepatocytes in primary culture [8,19-211 
evolves through gene activation and de novo syn- 
thesis of P-adrenoceptors (or, theoretically, 
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another protein factor required for receptor ac- 
cessibility or binding function). The close correla- 
tion between the progressive increase in the activity 
of isoproterenol-sensitive adenylate cyclase and 
binding of [‘251]cyanopindolol (fig.2) further sug- 
gests that the availability of functional receptors is 
rate-limiting for the &adrenergic response in these 
cells. 
Although it is not yet clear why the up- 
regulation of ,&adrenergic mechanism is elicited 
when the hepatocytes are kept in culture, our 
results show that it is not a consequence of the for- 
mation of attached monolayers and is not induced 
by any constituent of serum. One obvious 
possibility is that the ,&adrenergic binding and ef- 
fect increases in vitro due to release of the cells 
from a down-regulated state imposed upon them in 
vivo by endogeneous catecholamines. That this is 
at least a contributing factor seems likely in view of 
the dose-dependent suppression of isoproterenol- 
sensitive adenylate cyclase exerted by this agonist 
when added repeatedly to the cells during the 
culturing (fig.5). It is hard to compare directly 
these experiments (where isoproterenol was added 
at 3-hourly intervals) with the in vivo situation. 
However, the suppression started at low concen- 
trations of isoproterenol (between low9 and 
lo-’ M). 
In vivo the &adrenergic responsiveness of the 
liver appears to be subject to a complex regulation 
[5-181. Primary hepatocyte cultures may provide 
clues to a better understanding of the concerted ac- 
tions of the factors that govern the response of 
liver cells to .&adrenergic activation. Thus, it may 
be possible to examine if agents that lower the 
hepaticb-response in vivo, such as glucocorticoids, 
insulin and thyroid hormones, but which did not in 
our experiments counteract the increase in 
catecholamine-sensitive adenylate cyclase (table 3), 
facilitate the agonist-induced esensitization of the 
&response. This hypothesis is currently being 
tested in our laboratory, as part of a more 
systematic study of the mechanisms involved in up- 
and down-regulation of the fl-adrenergic respon- 
siveness of the hepatocytes. 
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